Glass Flakes Found in Anemia Drugs
Alan RipkaOctober 01, 2010 1:21 PM
On September 24, 2010, Amgen announced that certain lots of anemia drugs Epogen and Procrit vials are being voluntarily recalled because they may contain glass flakes. These drugs are used to treat anemia related to HIV therapy, chronic renal failure, and chemotherapy. The manufacturer, Amgen, was reckless in allowing these drugs to be sold on the market, says Alan Ripka, Esquire.
The glass flakes result from the interaction of the product with the glass vials they were stored in over the shelf life of the product. The drugs are being recalled from specialty distributors, wholesalers, pharmacies and healthcare providers as a precaution. The recall is being conducted in cooperation with the United States Food and Drug Administration.
Although users have not made any complaints yet, the potential serious effects include vein swelling caused by blood clots, immune system reactions, and irritation at the injection site.
Consumers should contact their physician or healthcare provider if they experience any problems that may be related to taking or using this drug product. Adverse events that may be related to the use of this product may also be reported to the United States Food and Drug Administration’s (FDA) MedWatch Adverse Event Reporting Program.
If you or any of your loved ones feel that you may have been harmed by using Epogen and Procrit for anemia, call Alan Ripka to discuss your claim. The professional team of lawyers at Napoli Bern Ripka law firm can evaluate your situation and determine the next steps to gain justice for you and your family. Napoli Bern Ripka, LLP has fought against all kinds of companies in other matters and will fight for you if we believe you have a potential case for medical malpractice, products liability, or personal injury. They are prepared to go to court and have a trial if necessary. Please fill out the form and submit or call and ask for Alan Ripka, one of our partners. Please specifically mention that you read the blog when contacting our office.